哪类型的患者是不能够用雷帕鸣

(Sirolimus) is a non-nephrotoxic immunosuppressant. It is mainly used in clinical practice for patients aged 13 or above who have received kidney transplants to prevent organ rejection, and the therapeutic effect is significant.

In recent years, rapamin (sirolimus), as a first-line drug for liver and kidney transplantation, has been marketed in 14 countries including Japan and the United States. Clinical experiments have shown that rapamycin (sirolimus) has good efficacy in heart, lung, intestinal, bone marrow and other transplants. At the same time, FK506 also plays an active role in the treatment of autoimmune diseases such as atopic dermatitis (AD), systemic lupus erythematosus (SLE), and autoimmune eye diseases.

While rapamycin (sirolimus) is immunosuppressive, it has received clinical attention because of its non-nephrotoxicity, anti-tumor and ability to reduce cytomegalovirus infection. On the premise that the quality of the donor kidney is satisfactory, the immune risk is small, the primary kidney disease is not closely related to massive proteinuria, and patients who are not prone to delayed wound healing after surgery can consider using sirolimus in the early stage after kidney transplantation; when sirolimus is used in the early stage after kidney transplantation, appropriate antibody induction protocols should be used, and the drug concentration should be closely monitored. When switching from calcineurin inhibitor drugs to rapamin (sirolimus) after kidney transplantation, the age of the donor, the time since the kidney transplantation at the time of switching, the patient's renal function at the time of switching, pathological tissue damage score, and urinary protein level are all important factors that affect the switching effect.

Foreign studies have also found that for liver transplant patients with preoperative renal insufficiency, prompt replacement of rapamycin (sirolimus) within 3 months after surgery can significantly improve renal function, while replacement after 1 year has no significant improvement in renal function. In lung transplantation, low-dose CNI combined with sirolimus can improve creatinine clearance in lung transplant recipients. Whether the patient can use it for treatment depends on the individual's constitution and condition, and the patient should take the medicine according to the doctor's recommendations.

Recommended related hot articles: /newsDetail/80212.html